Media kit

For press and media inquiries, please contact media@​egenesis.​com.

About eGenesis

eGenesis is a clinical-stage biotechnology company developing human-compatible engineered organs to address the severe global organ shortage. The Company’s proprietary genome engineering platform enables extensive, multiplex gene edits to remove key biological barriers, add protective human transgenes, and inactivate endogenous retroviruses. EGEN-2784, a genetically engineered porcine kidney, is the Company’s lead program and is currently being evaluated in a multi-patient Expanded Access study at MGH. eGenesis is headquartered in Cambridge, MA. 

A comprehensive overview of eGenesis’s technology, pipeline, and team. It includes our therapeutic approach, clinical development status, competitive advantages, and key milestones.